索拉非尼联合三氧化二砷治疗肝癌的研究

目的探讨索拉非尼联合三氧化二砷(As2O3)对肝癌的治疗作用。方法采用MTT实验检测索拉非尼联合As2O3对肝癌细胞的毒性。流式细胞仪检测索拉非尼联合As2O3诱导肿瘤细胞凋亡。构建肝癌异位瘤模型,检测索拉非尼联合As2O3对肝癌荷瘤裸鼠生存期的影响。结果与生理盐水组和单独给药组相比,联合干预组对肝癌具有更强的细胞毒性,差异具有统计学意义(P0.05)。细胞凋亡实验结果表明,联合干预能够促进肿瘤干细胞凋亡,差异具有统计学意义(P0.01)。体内治疗实验结果显示,索拉非尼与As2O3联合干预能够显著延长荷瘤小鼠的中位生存期,诱导肿瘤细胞的凋亡。结论索拉非尼联合As2O3能够增强对肝癌HepG2细胞的增殖抑制作用,是一种潜在的肝癌有效治疗方法。

The study of Sorafenib combined with As2O3 in treatment of hepatoma

Objective To evaluate the effect of Sorafenib combined with As2O3 in treatment of hepatoma.Methods The MTT assay was used to evaluate the anti-proliferation efficiency of As2O3 combined with Sorafenib.Flowcytometry was used to evaluate the HepG2 cells induced apoptosis by Sorafenib and As2O3.HepG2 cells were transplanted in mice to establish the animal model,which were used to evaluate the effect of anti-tumor.Results Compared with saline group,Sorafenib group and As2O3 group,the As2O3 ＋ Sorafenib group could inhibit the growth of HepG2 cells effectively （P ＜ 0.05）.Apoptosis experiments results showed that the joint intervention could promote apoptosis of cancer stem cells,and there was a statistically significant difference （P ＜ 0.01）.Experimental results in vivo treatment showed that Sorafenib and As2O3 joint intervention could significantly prolong median survival of nude,and induce apoptosis of tumor cells.Conclusion The As2O3 combined with Sorafenib can inhibit the growth of HepG2 cells and may be a potentially effective treatment for hepatoma.